« Return to News | CROs/Service Providers

Quintiles Adds Suite of PI3K Biomarker Assays

Monday, June 14, 2010 09:38 AM

Quintiles has expanded its offerings to include a comprehensive suite of biomarker assays to help biopharmaceutical companies investigate the phosphoinositide 3-kinases (PI3K) cancer survival pathway, the focus of numerous anti-cancer therapies under development.

Understanding the PI3K pathway is essential in developing new medicines to inhibit or block this pathway, thereby cutting off a metabolic function needed for certain cancers to survive.

Quintiles Global Central Laboratories said it is the only central lab with a comprehensive set of tissue analysis tools, including proprietary assays focused on the PI3K pathway. Quintiles’ suite of PI3K assays can help researchers determine if the PI3K pathway has been “activated” in a particular cancer patient, indicating that an investigational therapy targeting the PI3K pathway may be appropriate for that patient. Quintiles’ PI3K biomarker solutions are also useful in exploratory studies to retrospectively determine a tumor’s PI3K molecular profile.

 "P13K is an important target for many biopharmaceutical companies,” said Sarah Bacus, Ph.D., senior vice president and chief scientific officer, Translational Medicine Oncology, Quintiles. “Understanding this pathway will help support the clinical development of targeted therapies to this pathway and advances in personalized medicine.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.